Top
image credit: Marco Verch / CC BY 2.0 / Flickr

Analysts cheer ‘surprisingly positive’ AstraZeneca U.S. trial data

March 22, 2021

Via: CNBC

Health-care analysts welcomed AstraZeneca’s findings of hotly anticipated late-stage U.S. trial results for its Covid-19 vaccine.

The trial of more than 30,000 participants in the U.S., Peru and Chile found that the vaccine had an overall efficacy of 79% in preventing symptomatic Covid and was 100% effective in preventing severe disease and hospitalization.

Efficacy was consistent across age and ethnic groups, with 80% efficacy in participants at least 65 years old. The vaccine, known as AZD1222 and developed with the University of Oxford, was well-tolerated and the independent data safety monitoring board identified no safety concerns related to the vaccine, the company said Monday.

Read More on CNBC